SM
SRNE

Sabby Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Sabby Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21,897
Closed -$13.2M – 207
2021
Q4 		$13.2M Buy
21,897
+51
+0.2% +$317 1.92% 6
2021
Q3 		$16.7M Buy
21,846
+1,604
+8% +$13.6K 2.25% 8
2021
Q2 		$19.6M Buy
20,242
+1,936
+11% +$15.4K 2.77% 4
2021
Q1 		$15.1M Buy
18,306
+9,142
+100% +$96.5K 2.95% 8
2020
Q4 		$6.25M Buy
9,164
+2,021
+28% +$16.2K 1.2% 19
2020
Q3 		$7.96M Sell
7,143
-2,938
-29% -$26.9K 1.19% 18
2020
Q2 		$6.33M Buy
10,081
+8,512
+543% +$32.6K 1.27% 16
2020
Q1 		$289K Sell
1,569
-1,902
-55% -$5.48K 0.12% 46
2019
Q4 		$1.17M Buy
+3,471
New +$8.28K 0.33% 16

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Sabby Management's SRNE Position: Q1 2022 in Review

Sabby Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2022, closing a stake of 2,189,700 shares — an estimated $10.2M sold.

Sabby Management first reported a position in SRNE in Q4 2013 and held it in 15 quarters. The position peaked at $13M in Q3 2021. 235 funds tracked by Wall St. Rank hold SRNE as of Q1 2022.

  • Sabby Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
  • Sabby Management sold 2,189,700 Sorrento Therapeutics, Inc. shares in Q1 2022, an estimated $10.2M.
  • Sabby Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2013 and held it in 15 quarters.
  • Sabby Management's Sorrento Therapeutics, Inc. position peaked at $13M in Q3 2021.
  • 235 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2022.

Based on Sabby Management's 13F filing for Q1 2022, filed 16 May 2022.